Latest news with #Bio-E3
Hindustan Times
6 days ago
- Business
- Hindustan Times
IIT Indore, Mehta Family Foundation partner to launch 2 academic schools in Sustainability and Biomedical Engineering
Indian Institute of Technology (IIT) Indore today announced a partnership with the Bhupat & Jyoti Mehta Family Foundation (MFF),establish two new academic schools: Mehta Family School of Sustainability and Mehta Family School of Biosciences and Biomedical Engineering. IIT Indore, Mehta Family Foundation Partner to launch 2 academic achools(Handout) Also read: IIT Bombay launches certificate course in 'Supply Chain Analytics with AI & ML,' enrolments open; check details The Mehta Family School of Biosciences and Biomedical Engineering will be a pioneering academic and research hub at the intersection of Biology, Technology, Data, and AI, the institute said. The Mehta Family School of Sustainability will be an institution dedicated to climate-conscious innovation, leadership, and knowledge creation and will launch India's first BTech program in Environmental Economics and Sustainable Engineering, the institute informed. Also read: IIT-Guwahati students protest fee rise; management says 'small group' against hike The formal exchange of the Memorandum of Understanding (MoU) took place in New Delhi in the presence of Prof. Abhay Karandikar, Secretary, Department of Science & Technology; Dr. Rajesh S. Gokhale, Secretary, Department of Biotechnology; . Rahul Mehta, Founder of the Mehta Family Foundation; Dr. Suhas Joshi, Director, IIT Indore; Prof. Gobardhan Das, Director, IISER Bhopal; and Prof. Devendra Jalihal, Director, IIT Guwahati, in the presence of Prof. Shankar Subramaniam, University of California, San Diego; Prof. Ananth Y Grama, Purdue University; and Prof. Rajesh Gupta, University of California, San Diego, among other distinguished guests from the IIT academia. Prof. Abhay Karandikar, Secretary, Department of Science & Technology, said, '…The Mehta Family Foundation's ability to identify thematic areas that closely mirror the government's science and technology priorities is commendable. Such efforts strengthen India's innovation ecosystem and contribute meaningfully to our long-term national goals in research and education.' Dr. Rajesh S. Gokhale, Secretary, Department of Biotechnology, said, 'It's inspiring to see the convergence of engineering and biology being harnessed to address future's grand challenges. IITs are nurturing a vibrant biotech ecosystem, and the Mehta Family Foundation's initiatives are adding significant momentum. Their long-term vision and clear scientific agendas align well with emerging national frameworks like the Bio-E3 policy. This kind of support helps industrialise innovation and ensures India continues to lead across key science and technology parameters globally.' Dr. Suhas Joshi, Director of IIT Indore said this partnership with is the first single largest philanthropic contribution to IIT Indore. '... MFF, along with its financial support, brings a deep network of academic expertise, industry leaders, and international collaborators. Together, we aim to set new benchmarks in interdisciplinary education and research that addresses critical societal issues.
Hans India
22-06-2025
- Politics
- Hans India
Last 10 years have seen poor youths getting selected for top Civil Services jobs: Jitendra Singh
Union Minister Dr Jitendra Singh said that the last 11 years under the leadership of Prime Minister Narendra Modi have seen a democratisation of India's Civil Services with youths from poor families and remote areas getting selected for the country's top jobs and realising their aspirations. In an interview to Doordarshan News, the minister said that while at one time, the IAS and Civil Services were confined only to a handful of States like Bihar, Tamil Nadu, Kerala etc, today, we get toppers from the States which earlier hardly figured in the civil services list toppers from Punjab, Haryana and J&K. He cited the case of Parsanjit Kour, the young girl from Poonch, a border district in J&K, who made it to All India Rank 11 in the Civil Services Exam of 2022 in very first attempt or the boy from Punjab, Anmol Sher Singh Bedi who got All India Rank 2 in the Civil Services Exam of 2016. This, the Minister said, has restored faith in the objectivity and equal opportunity offered by the system and, thus, also led to democratisation of youth aspiration. 'This is the true essence of democracy -- where every mother, regardless of her socio-economic standing, has the confidence to believe that her child can reach the top," said Dr Jitendra Singh. The Minister said that the 11 years have been nothing short of transformational for India. 'What generations longed for over decades has been made possible in just over a decade,' he stated, adding that PM Modi has wiped the tears of the past and replaced them with eyes full of hope and future aspirations. Each passing year, the Minister said, has marked a new milestone -- be it in infrastructure, governance, technology, or youth empowerment -- creating unprecedented opportunities for every Indian. Union Minister of State (Independent Charge) for Public Grievances and Pensions, Dr Jitendra Singh, stated that under PM Modi's leadership, citizens' self-esteem has been restored. Referring to the PM's historic 2016 call of "Start-Up India, Stand-Up India", he emphasised how it broadened the employment horizon beyond traditional government jobs. 'It was only then people realised that job doesn't only mean "Sarkari Naukri", but also innovation, enterprise, and startups,' the Minister noted. India's biotech sector, he highlighted, is a perfect example -- growing from just 50 start-ups in 2014 to over 10,075 in 2024, with a leap in valuation from $10 billion to nearly $170 billion. He credited this to strong public-private partnerships and forward-thinking policies like Bio-E3 and the National Quantum Mission.
United News of India
10-06-2025
- Health
- United News of India
Experts meet to boost monoclonal antibody innovation in India
New Delhi, June 10 (UNI) Leading voices from the pharmaceutical industry, biotech start-ups, funding agencies such as BIRAC, and premier academic institutions convened on Tuesday to explore new strategies for accelerating monoclonal antibody (mAb) therapies in India. Such a therapy uses antibodies, made in a lab, to target and treat specific diseases, including cancer. The symposium, organised by the Translational Health Science and Technology Institute (THSTI), highlighted India's rapidly growing biopharmaceutical sector and noted the vast potential for indigenous innovation in the development of mAb therapies—critical tools in precision medicine. A recurring theme throughout the discussions was the need for early and sustained collaboration between academia and industry, particularly at the innovation and discovery stages. Such partnerships, experts agreed, are vital to developing affordable, homegrown technologies that serve national healthcare needs, said a statement from the Union Science and Technology. Prof. Jayanta Bhattacharya, Dean of THSTI, stressed that bridging the gap between scientific research and industrial application is essential to ensure India's self-reliance in biologics. Echoing this, Prof. G. Karthikeyan, Executive Director of THSTI, highlighted the importance of establishing innovation clusters where industry and academia can collaborate closely. These clusters, he said, would also serve as talent hubs, fostering the next generation of skilled professionals. Dr. Alka Sharma, Senior Adviser at the Department of Biotechnology (DBT), outlined the government's Bio-E3 policy (Biotechnology for Economy, Environment & Employment). She reaffirmed DBT's commitment to advancing mAb platforms, which are vital for addressing complex diseases and ensuring equitable access to high-quality biologics. She emphasised that the Bio-E3 initiative aims to build biotech self-reliance, reduce dependency on imports, and strengthen domestic R&D capacity through targeted investments in technologies like mAbs. The symposium served as a dynamic platform for cross-sector dialogue, reinforcing the belief that strategic collaboration and policy support are key to unlocking India's full potential in the global biopharmaceutical landscape, added the statement. UNI AJ SSP
Business Standard
06-05-2025
- Business
- Business Standard
Premas Life Sciences and Sphere Bio Unite to Advance Single-Cell Research in South Asia
India PR Distribution New Delhi [India], May 6: Premas Life Sciences Pvt. Ltd. (PLS), a pioneering enabler of life science innovations in India, has announced a strategic collaboration with Sphere Bio, a global leader in picodroplet-based microfluidic technologies for functional single-cell analysis. This partnership represents a significant leap in bringing transformative, next-generation platforms to scientists and researchers in India and Bangladesh. The collaboration is rooted in a shared vision: empowering biopharma, biotech, and academic communities with cutting-edge tools that accelerate discovery and drive impactful science. With this alliance, Premas will bring Sphere Bio's high-performance solutions - including their flagship Cyto-Mine® platform and a growing assay portfolio - closer to researchers in South Asia, supported by localized technical expertise and seamless implementation support. Sphere Bio, formerly known as Sphere Fluidics, is widely recognized for its innovations in single-cell and picodroplet microfluidics. Their technologies enable ultra-high-throughput analysis, sorting, and isolation of individual cells - critical for applications such as antibody discovery, cell line development, and advanced cell therapy research. These platforms are currently used by leading pharma companies and research institutions around the world to enhance the speed and accuracy of biologic development. For Premas Life Sciences, this partnership is a natural extension of its mission to democratize access to advanced life science tools. Over the last 18 years, PLS has built a strong legacy of introducing globally benchmarked technologies to India's scientific ecosystem - spanning genomics, proteomics, bioinformatics, and diagnostics. Their ability to not only introduce but also embed technologies through technical training, application support, and long-term scientific partnerships makes them uniquely positioned to amplify the impact of Sphere Bio's offerings. "India is entering a new era of biomedical innovation, with increased investments in biosimilars, vaccines, and cell and gene therapies. This collaboration with Sphere Bio allows us to deliver the kind of scientific capabilities that can transform how research is done in this region--faster, more precisely, and with greater reproducibility. With the government's strong push through initiatives like the Bio-E3 policy, PRIP scheme, and its vision for bio foundries, we believe technologies like Sphere Bio's Cyto-Mine® will play a crucial role in accelerating antibody discovery and cell line development, further strengthening the 'Made in India' biotech ecosystem. We're excited to co-create a future where access to such platforms is not a barrier but a baseline." said Praveen Gupta, Managing Director of Premas Life Sciences. Sphere Bio echoed this optimism. "We see South Asia as a region with enormous scientific potential. Our partnership with Premas is about more than market access - it's about long-term impact. Premas brings deep local understanding, technical know-how, and a genuine commitment to enabling discovery. Together, we aim to catalyse the next wave of breakthroughs in biologics and personalized medicine." said Dale Levitzke, CEO of Sphere Bio "Our partnership with Premas Life Sciences is a key milestone in our mission to make cutting-edge single-cell technologies more accessible across the APAC region. India and Bangladesh represent rapidly growing innovation hubs, and we see immense potential in empowering local researchers with tools that meet global standards. Premas brings deep market understanding, strong scientific engagement, and a track record of successful technology integration--making them an ideal partner to drive regional adoption and impact." said Jay Manikandan, VP Commercial (APAC), Sphere Bio This alliance comes at a pivotal time, as the biotech landscape in India and Bangladesh rapidly evolves with government backing, rising R & D investment, and a growing scientific workforce. As demand for next-gen therapeutics increases, so does the need for high-resolution, scalable tools--precisely what Sphere Bio delivers. Together, Premas and Sphere Bio are building a scientific bridge between global innovation and regional potential. Beyond product access, the partnership offers localized support, training, and tailored solutions aligned with international standards. It sets a new benchmark for how advanced technologies can be effectively introduced and scaled in emerging biotech markets.
